Citeq Biologics B.V.

Citeq Biologics B.V. is a Netherlands-based company specializing in the production of insect and mold allergens for professionals working in the field of allergy and asthma. Established in 1994, the company's primary focus lies in the production of house dust mites (HDMs) and their allergens. Citeq Biologics employs a unique cultivation technique that results in the generation of high concentrations of major allergens, contributing to the development of robust raw materials, extracts available in various purity grades, and exceptionally pure major allergens. Catering to manufacturing and pharmaceutical industries, the company offers a range of allergenic extracts and whole cultures, serving as crucial resources for researchers and diagnostics within the field. To learn more about Citeq Biologics B.V., please visit their website at www.citeqbiologics.com.

As of the latest available data, no specific details regarding the last investment or the involved investors have been documented for Citeq Biologics B.V. This signifies a potential opportunity for venture capital firms seeking to invest in a company within the niche field of allergenic extracts and cultures, presenting a chance to be a part of a unique and specialized market with a company that boasts over 25 years of industry experience. With its long-standing presence, specialized focus, and innovative approach, Citeq Biologics B.V. could prove to be an appealing prospect for investors looking to diversify their portfolios within the pharmaceutical and manufacturing sectors.